

Cobicistat + elvitegravir + emtricitabine+ tenofovir alafenamide

The Expert Committee, after evaluation, declines to list the medicine proposed in the application.

The Model List of Essential Medicines reports reasons that Committee Members have identified for denying listing.

Rejected

General description

INN

Cobicistat + elvitegravir + emtricitabine + tenofovir alafenamide

ATC codes

[J05AR18](#)

Medicine type

Chemical agent

EML status history

Application rejected in 2017 ([TRS 1006](#)) for [Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

Wikipedia

[Cobicistat + elvitegravir + emtricitabine+ tenofovir alafenamide](#)

DrugBank

[Cobicistat](#),

[Elvitegravir](#),

[Emtricitabine](#),

[Tenofovir alafenamide](#)

Recommendations

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 150 mg + 150 mg + 200 mg + 10 mg

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)